Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M C Michel

Showing results (31-40 of 282) with videos related to

Pageof 29
Sort By:
Clinical and Experimental Hypertension. Part A, Theory and Practice|January 1, 1989
Interaction between alpha 2-adrenergic and NPY receptor pathways in human erythroleukemia cellsH J Motulsky, M C Michel
Trends in Pharmacological Sciences|September 1, 1989
Are there multiple imidazoline binding sites?M C Michel, P A Insel
The American Journal of Physiology|December 1, 1988
Neuropeptide Y mobilizes Ca2+ and inhibits adenylate cyclase in human erythroleukemia cellsH J Motulsky, M C Michel
Fundamental & Clinical Pharmacology|January 1, 1996
alpha-Adrenergic regulation of human renal functionM C Michel, L C Rump
The Journal of Clinical Investigation|September 1, 1996
Making sense out of antisense for the study of drug receptorsM C Michel, P A Insel
Naunyn-Schmiedeberg'S Archives of Pharmacology|August 1, 1994
Comparison of cloned and pharmacologically defined rat tissue alpha 1-adrenoceptor subtypesM C Michel, P A Insel
Deutsche Medizinische Wochenschrift (1946)|May 15, 1998
[Terazosin]R F Schäfers, M C Michel
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|December 1, 1992
Adrenergic receptors and their signal transduction mechanisms in hypertensionO E Brodde, M C Michel
British Journal of Clinical Pharmacology|January 1, 1990
Beta-adrenoceptor control of immune function in congestive heart failureA S Maisel, M C Michel
Trends in Pharmacological Sciences|October 1, 1989
Disease states can modify both receptor number and signal transduction pathwaysO E Brodde, M C Michel
Pageof 29

Showing results (31-40 of 282) with videos related to

Sort By:
Pageof 29
Clinical and Experimental Hypertension. Part A, Theory and Practice|January 1, 1989
Interaction between alpha 2-adrenergic and NPY receptor pathways in human erythroleukemia cellsH J Motulsky, M C Michel
Trends in Pharmacological Sciences|September 1, 1989
Are there multiple imidazoline binding sites?M C Michel, P A Insel
The American Journal of Physiology|December 1, 1988
Neuropeptide Y mobilizes Ca2+ and inhibits adenylate cyclase in human erythroleukemia cellsH J Motulsky, M C Michel
Fundamental & Clinical Pharmacology|January 1, 1996
alpha-Adrenergic regulation of human renal functionM C Michel, L C Rump
The Journal of Clinical Investigation|September 1, 1996
Making sense out of antisense for the study of drug receptorsM C Michel, P A Insel
Naunyn-Schmiedeberg'S Archives of Pharmacology|August 1, 1994
Comparison of cloned and pharmacologically defined rat tissue alpha 1-adrenoceptor subtypesM C Michel, P A Insel
Deutsche Medizinische Wochenschrift (1946)|May 15, 1998
[Terazosin]R F Schäfers, M C Michel
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|December 1, 1992
Adrenergic receptors and their signal transduction mechanisms in hypertensionO E Brodde, M C Michel
British Journal of Clinical Pharmacology|January 1, 1990
Beta-adrenoceptor control of immune function in congestive heart failureA S Maisel, M C Michel
Trends in Pharmacological Sciences|October 1, 1989
Disease states can modify both receptor number and signal transduction pathwaysO E Brodde, M C Michel
Pageof 29